Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma


Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Kenneth C Anderson, MD (1/22/13)

Shah J et al. A multi-center Phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Proc ASH 2012;Abstract 74.

Dr Anderson is Kraft Family Professor of Medicine at Harvard Medical School, Director of the Jerome Lipper Multiple Myeloma Center and Director of the LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute in Boston, Massachusetts.